Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

LYTAK1, a novel TAK1 inhibitor, suppresses KRAS mutant colorectal cancer cell growth in vitro and in vivo.

Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine - 1 May 2015

Zhou Jundong, Zheng Bing, Ji Jiansong, Shen Fei, Min Han, Liu Biao, Wu Jinchang, Zhang Shuyu

Abstract excerpt

KRAS mutation in colorectal cancer (CRC) activates transforming growth factor-β (TGF-β)-activated kinase 1 (TAK1) to promote tumor progression. In the current study, we explored the potential effect of LYTAK1, a novel TAK1 inhibitor, against KRAS mutant CRC cells in vitro and in vivo. We found th...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to HT29 Cells
Share to MAP Kinase Kinase Kinases
Share to MAP Kinase Signaling System

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Mice, Nude

Share to Proto-Oncogene Proteins p21(ras)

Share to ras Proteins

Share to Tumor Burden

Share to Xenograft Model Antitumor Assays

Source

Identifiers

PMID: 25524577
DOI: 10.1007/s13277-014-2961-2

Genes

KRAS
DLD

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026. Prepared record publication-25524577-2026-09-04.2. Manifest publication-graph-cohort-2026-09-04.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

LYTAK1, a novel TAK1 inhibitor, suppresses KRAS mutant colorectal cancer cell growth in vitro and in vivo.PMID 25524577Read ↗

TAK1 inhibition promotes apoptosis in KRAS-dependent colon cancers.Semantic proximity Read ↗

KRASG12C mutation-induced TOPK overexpression contributes to tumour progression in non-small cell lung cancer.Semantic proximity Read ↗

Brief report: Therapeutic benefit of ISA-2011B in colorectal cancer.Semantic proximity Read ↗

Crucial Role of Oncogenic KRAS Mutations in Apoptosis and Autophagy Regulation: Therapeutic Implications.Semantic proximity Read ↗

Multifaceted roles of TAK1 signaling in cancerSemantic proximity Read ↗

SNTB1 regulates colorectal cancer cell proliferation and metastasis through YAP1 and the WNT/β-catenin pathwaySemantic proximity Read ↗

Melatonin Downregulates PD-L1 Expression and Modulates Tumor Immunity in KRAS-Mutant Non-Small Cell Lung Cancer.Semantic proximity Read ↗

Targeting transforming growth factor-beta signaling in liver metastasis of colon cancer.Semantic proximity Read ↗

Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1.Semantic proximity Read ↗

HYL001, a new potent TGFβ signaling inhibitor that is efficacious against microsatellite stable CRC metastasis in combination with immune checkpoint therapy in miceSemantic proximity Read ↗

A novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growth.Semantic proximity Read ↗

Targeting c‐MET by LY2801653 for treatment of cholangiocarcinomaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.